Growth and Asymmetric diMethylArginine

Inclusion criteria

• Group A: GHD, defined by 2 GH peaks less than 6.6 ng/ml (20 mU/L) at two stimulation tests
• Group B: IUGR, defined by a birth length and/or a birth weight inferior to - 2 SD for gestational age according to Usher and McLean charts
• Group C: Control children matched to children matched to subjects of groups A and B, according to gender and age
• Informed consent signed by representative of the parental authority

Exclusion criteria

• Chronic disabling disease (ex: diabetes, severe asthma)
• Evolving cancer
• Severe psychiatric disorder (ex: autism, schizophrenia; severe depression)
• Hypothalamic tumor (ex: craniopharyngioma)
• Anamnesis of cranial irradiation
• Overweight, obesity or thinness
• Precocious puberty
• Non-replacing therapy by glucocorticoids or sex steroids less than 1 month before the exploration
• Anterior treatment by recombinant human GH
• Other conditions, treatments or habits impacting arterial reactivity: acrocyanosis, cryoglobulinemia, beta adrenergic blocking habits, tobacco smoking or other drug addictions, dyslipidemia
• Pregnancy or lactation
• Acute infection less than three weeks before the investigation
• Participation to a therapeutic protocol
• Impossibility for the representatives of the parental authority to understand the objectives of the protocol
• Absence of social security coverage. Refusal by the parents to sign the informed consent or oral refusal by the child to participate to the study